Search Results
Nov 04, 2025, 05:05 ET From Pandemic Innovation to Global Collaboration: Taiwan's TCM Shines at CPHI Frankfurt 2025
demonstrated multi-target antiviral and anti-inflammatory effects, reducing ICU admissions and mortality in COVID-19 patients while protecting against lung injury and post-infection brain fog. Participating Taiwanese enterprises —Chuang Song Zong, Li Kang Biotech, Timing
More news about: Taiwan Institute of Economic Research
Nov 03, 2025, 15:00 ET Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
i "Learn about Pulmonary Embolism," American Lung Association. Accessed on Oct. 7, 2025.
More news about: Penumbra, Inc.
Nov 03, 2025, 14:23 ET Vascarta Inc: Transdermal Curcumin (VAS-101 Drug Candidate) Interrupts the Neuroinflammatory Pathophysiological Cascade Associated with Acute Sickle Cell Crisis
and Hispanics in the United States. Individuals with sickle cell disease may experience serious health complications, such as chronic pain, stroke, lung problems, eye problems, infections, and kidney disease, along with periodic acute pain crises. Pain is a significant burden in the day-to-day lives
More news about: Vascarta Inc
Nov 03, 2025, 11:58 ET New Study Explores Placental Malperfusion's Impact on Fetal Health and Development in Congenital Heart Disease
Advancing Translational Sciences, National Institutes of Health (UL1TR001878), National Human Genome Research Institute (R01HG013355) and the National Heart Lung and Blood Institute (T32 HL007915-25). Josowitz et al. "Placental Malperfusion is Associated with Adverse Outcomes in Congenital
More news about: Children's Hospital of Philadelphia
Nov 03, 2025, 11:17 ET Tennessee Takes Action on Lung Health: Governor Lee Recognizes COPD Awareness Month
COPD is a progressive lung condition that makes it difficult to breathe and affects more than 30 million Americans—including nearly 490,000 Tennessee residents. In the state,
More news about: COPD Action Alliance
Nov 03, 2025, 10:19 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company
More news about: Faruqi & Faruqi, LLP
Nov 03, 2025, 09:00 ET Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
therapies in development for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), NRAS-mutant melanoma, non-small cell lung cancer with mutation or amplification of MET, and X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). Pierre Fabre Pharmaceuticals is headquartered
More news about: Pierre Fabre Pharmaceuticals
Nov 03, 2025, 08:30 ET IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
surgery, which has a 5-year OS of 67% - 82% according to published studies Lung cancer is the most frequently diagnosed cancer worldwide with an incidence of 2.5 million cases and remains the leading cause of cancer-related death
More news about: IceCure Medical
Nov 03, 2025, 08:30 ET Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
lead product candidate, is a novel, first-in-class, and multi-indication Actinium-225 (Ac-225) in development for prostate cancer and non-small cell lung cancer (NSCLC). The antigen specifically targeted by ATNM-400 is highly expressed in metastatic castration-resistant prostate cancer (mCRPC), contributes
More news about: Actinium Pharmaceuticals, Inc.
Nov 03, 2025, 08:00 ET Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND
metastatic locations. The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage,
More news about: Matica Biotechnology, Inc.
Nov 03, 2025, 05:01 ET LUNGevity Foundation Launches 2025 Lung Cancer Awareness Month with 60,000 White Flags on the National Mall in Washington DC
About Lung Cancer in the US About 1 in 18 Americans will be diagnosed with lung cancer in their lifetime. More than 226,000 people in the US will be diagnosed with lung cancer this year,
More news about: LUNGevity Foundation
Nov 03, 2025, 03:09 ET aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
that, "aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing it in patients with a type of lung disease known as pulmonary sarcoidosis, which impacts the lungs and lymph nodes." Based on this news, shares of aTyr traded down by more than 81% in
More news about: DJS Law Group LLP
Nov 02, 2025, 23:12 ET Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
approval from the China National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) after EGFR-TKI therapy. This approval made ivonescimab the world's first bispecific antibody based on a synergistic "immunotherapy
More news about: Akeso, Inc.
Nov 02, 2025, 22:24 ET SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly,
More news about: THE ROSEN LAW FIRM, P. A.
Nov 02, 2025, 08:00 ET OncoHost to Present Two Posters Highlighting Advances in Plasma Proteomics Monitoring and Prediction for NSCLC at ISLB 2025
transformative potential of plasma proteomics in improving clinical decision-making and real-time disease monitoring for patients with non-small cell lung cancer (NSCLC). Poster 1: Plasma Proteomics as a Systemic Monitoring Approach in NSCLC Immunotherapy:
More news about: OncoHost
Nov 01, 2025, 05:02 ET LUNGevity Foundation Leads 2025 Lung Cancer Awareness Month to Drive Research, Awareness, and Early Detection
critical awareness and meaningful change in the lung cancer community. Lung Cancer Awareness Month reinforces that anyone with lungs can get lung cancer. Through groundbreaking research, education, and advocacy, LUNGevity is driving progress toward a future where lung cancer is detected early, treated effectively,
More news about: LUNGevity Foundation
Oct 31, 2025, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 27, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 27,582
More news about: TransMedics Group, Inc.
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
adizutecan) as a monotherapy or in combination across advanced, solid tumors, as well as new analysis of ABBV-706 for the treatment of R/R small cell lung cancer (SCLC). At the Society of Hematologic Oncology (SOHO) Annual Meeting, AbbVie announced updated results
More news about: AbbVie
Oct 31, 2025, 07:00 ET Brainomix Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation
Oct. 31, 2025 /PRNewswire/ -- Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced it has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network.
More news about: Brainomix
Oct 31, 2025, 06:22 ET Weekly Recap: 13 Health Press Releases You Need to See
Research Centers (ACRC) Network, and key strategic research collaborations focused on finding ways to identify, treat, and ultimately cure lung disease. The Lung Association's commitment comes amid a challenging year for public health and scientific research in the United States, marked by funding cuts
More news about: PR Newswire
Oct 30, 2025, 12:45 ET Healthcare Providers Describe Exclusive Human Milk Diet as 'Critical' Need for Premature Infants
as delivery 37 weeks before gestation, remains a major contributor to infant mortality and morbidity. Very preterm infants face heightened risks of lung, brain and bone development issues, as well as intestinal diseases such as necrotizing enterocolitis (NEC). Growing research demonstrates that an exclusive
More news about: National Coalition for Infant Health
Oct 30, 2025, 11:00 ET Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 40th Anniversary Annual Meeting
(1328) SSGJ-707, a PD-1/VEGF bispecific antibody, combined with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC): results from a phase 2 study Lin Wu, PhD –Hunan Cancer HospitalSession 107d: The Next Wave: Viruses, Cells
More news about: Society for Immunotherapy of Cancer (SITC)
Oct 30, 2025, 10:59 ET First Dual-Positive Immunotherapy with PFS and OS Benefit in EGFR+ NSCLC After EGFR-TKI Progression: Ivonescimab Final OS Analysis from HARMONi-A to Be Presented at SITC 2025
first-in-class bispecific antibody ivonescimab (PD-1/VEGF bispecific antibody) combined with chemotherapy for EGFR-mutated, non-squamous non-small cell lung cancer (NSCLC) patients after EGFR-TKI progression, have been selected as a Late-Breaking Abstract at the 40th Annual Meeting of the Society for Immunotherapy
More news about: Akeso, Inc.
Oct 30, 2025, 10:30 ET Cystic Fibrosis (CF) Therapeutics Market to Reach $17.1 billion by 2027 in the short term and $32.3 billion by 2034 Globally, at 9.6% CAGR: Allied Market Research
heightened R&D investments have propelled innovation in drug development, with new therapies targeting specific mutations and aiming to improve lung function. Further, the prevalence of CF, particularly in developed regions, further drives market growth, as more patients require access to effective
More news about: Allied Market Research
Oct 30, 2025, 08:00 ET ChemDiv's Discovery Platform Enables Differentiated, Reversible Pan‑EGFR Kinase Inhibitors for GFR‑Mutant Lung Cancer
platform. The new capabilities strengthen support for partners developing reversible pan‑EGFR inhibitors for EGFR‑mutant NSCLC (non‑small cell lung cancer). This upgrade integrates AI‑guided chem‑bio design, kinome‑wide selectivity modeling, and parallel synthesis to deliver candidates with broad
More news about: ChemDiv